← Research library

Trekrezan and PGC‑1α expression in rat muscle — RU2460524C1

Patent disclosure · 2012

What the patent describes
Sixty Wistar rats (180–200 g) were divided among matched-volume saline, 10 mg/kg Trekrezan or 25 mg/kg Trekrezan intraperitoneally for seven days. Per-arm sizes are unstated. Rats swam with an 8% body-weight load and underwent a hanging-grid test. Muscle was then assayed for PGC‑1α mRNA and relative mitochondrial DNA.
Reported evidence
In 60 rats, the patent reports swim times of 33.50 minutes with saline, 48.00 with 10 mg/kg Trekrezan and 52.30 with 25 mg/kg.

Loaded swimming time · 33.50 ± 1.70 vs 48.00 ± 2.40 and 52.30 ± 2.60 minutes · Saline vs 10 and 25 mg/kg, respectively

Reported patent results

Reported findings

In 60 rats, the patent reports swim times of 33.50 minutes with saline, 48.00 with 10 mg/kg Trekrezan and 52.30 with 25 mg/kg.

Sixty Wistar rats (180–200 g) were divided among matched-volume saline, 10 mg/kg Trekrezan or 25 mg/kg Trekrezan intraperitoneally for seven days. Per-arm sizes are unstated. Rats swam with an 8% body-weight load and underwent a hanging-grid test. Muscle was then assayed for PGC‑1α mRNA and relative mitochondrial DNA.

Population or model Sixty Wistar rats (180–200 g) were divided among matched-volume saline, 10 mg/kg Trekrezan or 25 mg/kg Trekrezan intraperitoneally for seven days. Per-arm sizes are unstated. Rats swam with an 8% body-weight load and underwent a hanging-grid test. Muscle was then assayed for PGC‑1α mRNA and relative mitochondrial DNA.

Results · Original Russian grant, methods and Tables 1–3.
MeasureResultComparison, timing and statistics
Loaded swimming time33.50 ± 1.70 vs 48.00 ± 2.40 and 52.30 ± 2.60 minutesSaline vs 10 and 25 mg/kg, respectively
Hanging-grid time11.45 ± 0.58 vs 15.45 ± 0.77 and 16.35 ± 0.82 minutesSame group order
PGC‑1α mRNA relative to β-actin0.90 ± 0.10 vs 1.72 ± 0.15 and 1.90 ± 0.20Same group order
Relative mitochondrial DNA per diploid genome0.90 ± 0.10 vs 1.15 ± 0.10 and 2.25 ± 0.20Same group order
Rat exercise and muscle measures reported in Tables 1–3
Rat exercise and muscle measures reported in Tables 1–3
MeasureSaline10 mg/kg25 mg/kg
Loaded swimming time (minutes)33.50 ± 1.7048.00 ± 2.4052.30 ± 2.60
Hanging-grid time (minutes)11.45 ± 0.5815.45 ± 0.7716.35 ± 0.82
Relative PGC‑1α/β-actin mRNA0.90 ± 0.101.72 ± 0.151.90 ± 0.20
Relative mtDNA per diploid genome0.90 ± 0.101.15 ± 0.102.25 ± 0.20

Values with uncertainty as printed in the patent. The animal count of 60 is for the experiment as a whole.

The disclosed RNA and DNA assays are indirect mitochondrial measures. The experiment does not show how Trekrezan affects human endurance.

Source for these results ↗ · Reviewed 2026-11-15

Patent claims and provenance

Use. Claims a Trekrezan use involving expression of the mitochondrial biogenesis regulator PGC‑1α.

The supporting experiment used rats. The filing reports relative muscle markers and exercise tests. Direct mitochondrial respiration and human outcomes were outside the experiment.

Publication
RU2460524C1 ↗ · 2012-09-10
Earliest priority / filing
2011-04-12 / 2011-04-12
Original applicant / assignee
Maksud M. Rasulov
Indexed status
Not shown; official status unverified · checked 2026-11-15
Patent family
46938825 · family publications are related filings, not independent studies.
Original title, inventors and related publications

Средство, стимулирующее экспрессию гена коактиватора PGC-1α

Inventors: M. M. Rasulov; M. K. Nurbekov; M. G. Voronkov; S. N. Bobkova; O. A. Belikova; M. V. Zvereva; N. P. Shimanovskaya; O. A. Speranskaya.

RU2460524C1

Original patent PDF ↗

Patent collection and status interpretation →

Study limitations and source details

Study limitations

  • The supporting experiment used rats. The filing reports relative muscle markers and exercise tests. Direct mitochondrial respiration and human outcomes were outside the experiment.
  • The disclosed RNA and DNA assays are indirect mitochondrial measures. The experiment does not show how Trekrezan affects human endurance.
  • Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
  • Status labels are Google Patents index snapshots for the displayed publication or application; each record lists the review date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.

Related publications may describe some of the same participants or experiments.

Source details

Patent publication · Original patent text and indexed metadata

Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.

Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.

Sources checked

Citation

Published

Patent / reported experimentsFull text available

M. M. Rasulov, M. K. Nurbekov, M. G. Voronkov, S. N. Bobkova, O. A. Belikova, M. V. Zvereva, N. P. Shimanovskaya, O. A. Speranskaya. Trekrezan and PGC‑1α expression in rat muscle — RU2460524C1 RU2460524C1 · patent family 46938825

Study source ↗ · Bibliography entry · Link to this summary

Related compounds

Editorial policy and evidence standards